Bloomberg-backed cancer drug summit aims to thaw US-China relations – Endpoints News – Community News
Us China

Bloomberg-backed cancer drug summit aims to thaw US-China relations – Endpoints News

A new coalition will be launched next week in Singapore in an effort to accelerate cancer drug development and improve research collaboration between the US and China, despite mounting tensions.

Launched by billionaire Michael Bloomberg’s economic forum called the Bloomberg International Cancer Coalition, it will bring together the top drug execs from the countries with the two largest cancer populations in the world. The coalition will push for new standards for cancer drugs and cool temperatures that have risen during the Covid-19 pandemic.

Representatives from several leading drug manufacturers will attend, including J&J, Bayer, Roche, Novartis, BeiGene, Zai Lab and academic institutions from China, the US and Europe.

Some current and former diplomats will also be in attendance, but representatives from China and the health regulator have not yet said whether they will be in Singapore, the Financial times reported on Sunday.

A diplomat, former Prime Minister of Australia and head of the Asia Society, Kevin Rudd, told: FT the effort to reduce the pandemic-induced saber clatter is akin to the 1970s deceleration between the US and China, in which the countries used table tennis as a way to thaw Cold War hostilities.

“The relationship between the US and China has gotten so bad that we at the Asia Society have formed the idea that cancer treatment trials may well become the next iteration of ping pong diplomacy to get this relationship back on track,” he said. FT.

Rudd added that disagreements over intellectual property are likely to be discussed at the summit.

The report also noted that the group will attempt to use the FDA’s Project Orbis as a model to streamline the submission of new drugs outside the US. Amgen’s cancer drug Lumakras was approved in several countries under the project in May, and regulators from the US, Australia, Brazil, Canada and the UK reviewed Amgen’s submission simultaneously.

During the pandemic, several issues have emerged as flashpoints, pushing US-China relations south. The main US concern has been China’s reluctance to allow a full investigation into the origin of the novel coronavirus, with Chinese authorities blocking WHO researchers from accessing some data earlier this year.

After that group released its report in February, the WHO announced a second attempt in July to investigate the origins of the pandemic. But China said it could not accept the new terms because it included a new provision to investigate whether the coronavirus may have leaked from a Chinese lab. NPR reported at the time.

Early in the pandemic, a scientific consensus emerged that the SARS-CoV-2 virus jumped from animals to humans, but a report says a US intelligence agency has not ruled out the “lab leak theory.” Four other agencies disagreed, while three others couldn’t say for sure in some way.

The WHO established a new scientific advisory group last month to investigate the origins of Covid-19.

About the author


Add Comment

Click here to post a comment